Patient-reported outcomes (PROs) are any report of a patient's health condition that comes directly from the patient, without interpretation by a clinician or anyone else. The FDA's 2009 guidance, "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims," established the framework for using PRO instruments to support claims in approved medical product labeling. Since then, FDA has issued additional patient-focused drug development guidances under the 21st Century Cures Act, and sponsors are collecting PRO data more frequently in pivotal trials.
But collecting PRO data that satisfies FDA is only half the challenge. Getting that same data to influence payer coverage decisions requires a different evidence strategy. The gap between regulatory PRO evidence and payer PRO evidence is wide, and most manufacturers do not discover it until after approval, when the AMCP dossier is being assembled and payer medical directors start asking questions that the pivotal trial PRO package was not designed to answer.
This article is for biotech clinical development leads, HEOR directors, medical affairs teams, and market access professionals who are designing PRO strategies for products in late-stage development. It maps the specific points where PRO evidence that works for FDA fails to work for payers, and it provides a framework for closing those gaps.
The regulatory PRO framework
FDA guidance structure
The FDA's patient-focused drug development guidance series, developed in response to the 21st Century Cures Act, consists of four documents:
- PFDD Guidance 1: Collecting comprehensive and representative input (June 2018)
- PFDD Guidance 2: Methods to identify what is important to patients (September 2019)
- PFDD Guidance 3: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments (June 2022)
- PFDD Guidance 4: Incorporating clinical outcome assessments into endpoints for regulatory decision-making (draft, 2023)
The 2009 PRO guidance remains the foundational document for evaluating PRO instruments used to support labeling claims. It describes how FDA reviews the content validity, construct validity, reliability, and ability to detect change of a PRO instrument before accepting it as the basis for a label claim.
What FDA requires for a PRO label claim
To support a labeling claim, a PRO instrument must be well-defined and reliable. FDA evaluates:
- Content validity: Does the instrument measure the concepts that are important to patients in the target disease? Content validity is established through qualitative research with patients, including concept elicitation interviews and cognitive debriefing.
- Measurement properties: Does the instrument produce consistent scores (reliability) and measure what it intends to measure (construct validity)? Are the scores responsive to clinically meaningful changes?
- Endpoint definition: Is the PRO endpoint clearly defined in the statistical analysis plan, including the specific instrument, the specific domain or item, the scoring algorithm, the time point, and the analysis population?
- Multiplicity control: If the PRO is one of several endpoints, is it properly positioned in the hierarchical testing strategy to control Type I error?
Only primary or key secondary endpoints can support a label claim. Exploratory PRO endpoints, no matter how well-measured, do not generate label language.
The COA Compendium
FDA maintains a Clinical Outcome Assessment (COA) Compendium that lists clinical outcome assessments, including PROs, that have been used in drug labeling or qualified through the Drug Development Tool (DDT) program. The Compendium is organized by disease/condition, context of use, concept measured, and COA type. FDA describes it as "a communication tool" and "a starting point when considering a COA for use in clinical trials," not as an endorsement or guarantee that a listed instrument will be accepted for any particular submission.
Where the regulatory-to-payer translation breaks down
Gap 1: Instrument unfamiliarity
FDA evaluates the psychometric properties of a PRO instrument on their merits. If a sponsor develops a new disease-specific PRO instrument with strong content validity and robust measurement properties, FDA may accept it for a labeling claim. Payers, however, gravitate toward instruments they already know.
A survey of managed care medical and pharmacy directors, published in the American Health and Drug Benefits journal, found that 54 percent thought health-related quality of life (HRQOL) information was "important" or "very important" for formulary decisions, but that familiarity with specific instruments varied widely. Payers are more comfortable evaluating data from well-established instruments like the EORTC QLQ-C30 (cancer), the HAQ-DI (rheumatoid arthritis), the ADAS-Cog (Alzheimer's disease), and the PASI (psoriasis) than from newly developed instruments, regardless of the new instrument's psychometric superiority.
The implication: if your pivotal trial uses a novel PRO instrument, plan a bridging strategy that includes at least one established comparator instrument alongside it, even if the established instrument is not the primary PRO endpoint.
Gap 2: Minimal clinically important difference (MCID)
FDA cares about whether the PRO endpoint shows a statistically significant difference between treatment arms. Payers care about whether the difference is clinically meaningful to patients. The threshold for clinical meaningfulness is the minimal clinically important difference (MCID).
If your pivotal trial shows a PRO improvement that is statistically significant but below the established MCID for the instrument, payers will discount it. A payer medical director reviewing an AMCP dossier does not need to conduct a formal MCID analysis; they simply compare the observed treatment effect against what the published literature says constitutes a meaningful change on that instrument.
The problem is that MCIDs are often not well-established for new instruments, or they are established in populations that differ from the trial population. If your PRO strategy does not include a pre-specified responder analysis based on a clinically meaningful threshold, the payer has no way to interpret the treatment effect in terms that are relevant to formulary decision-making.
Gap 3: Comparator context
Pivotal trials for regulatory approval often use placebo comparators. FDA accepts placebo-controlled PRO improvements as evidence of treatment benefit. But payers make coverage decisions in the context of existing therapies. A PRO improvement over placebo does not answer the payer's question: how does this drug compare to what is already on formulary?
The AMCP Format for Formulary Submissions 5.0, the current standard for payer evidence packages, explicitly requests comparative evidence against relevant therapeutic alternatives. If the pivotal trial PRO data are placebo-controlled only, the AMCP dossier must supplement with indirect treatment comparisons, network meta-analyses, or real-world evidence that contextualizes the PRO findings against active comparators. Many manufacturers discover this gap only when the dossier is being written, long after the trial design is locked.
Gap 4: Formulary-relevant population
Payers define populations by formulary tier, prior authorization criteria, and step therapy protocols. The pivotal trial population may not align with the payer's target population. For example, a trial may enroll biologic-naive patients only, but the payer's formulary places the drug on a tier that requires failure of one prior biologic. The PRO data from biologic-naive patients do not directly address the payer's question about PRO benefit in the population that will actually receive the drug under the coverage policy.
Gap 5: Time horizon
Many pivotal trials collect PRO data for the duration of the controlled treatment period, which may be 12 to 24 weeks. Payers are interested in longer-term outcomes: durability of PRO improvement over 6 to 12 months, PRO trajectory after treatment discontinuation, and PRO changes in the context of treatment switching. If the pivotal trial PRO data stop at week 24, the payer has no evidence to support formulary positioning beyond the acute treatment phase.
Gap 6: Open-label extension bias
Many sponsors attempt to address the time horizon gap by presenting PRO data from open-label extension (OLE) studies in the AMCP dossier. Payers discount OLE data because of selection bias: only patients who tolerated and responded to the drug in the controlled phase enter the OLE, and both patients and investigators know they are receiving the active drug. The PRO improvement in the OLE is not comparable to the blinded, controlled data. If the dossier relies heavily on OLE PRO data without acknowledging the bias, the payer review will flag it as a quality concern.
Payer survey evidence on PRO use in coverage decisions
A survey published in the American Health and Drug Benefits journal asked payer representatives to rate the value of PRO data in formulary decisions for oncology drugs on a 1-to-7 scale. The average response was 2.8, with the modal response being 2 (low value). No payer respondent rated PRO data at 6 or 7 (high value). A separate question asked whether PRO data can provide sufficient evidence that a drug is meeting an unmet need; the average response was 3.6, again indicating limited confidence.
However, the same survey found that 78 percent of payer respondents thought PRO evidence is useful for providing additional context for safety, and 47 percent said that formulary reviews would be at least somewhat influenced by a lack of PRO evidence from clinical trials. This indicates that PROs are not a primary driver of coverage decisions but serve as a secondary consideration that can tip a close decision or provide differentiation in a crowded therapeutic class.
A 2022 paper by Oderda and coauthors in the Journal of Managed Care and Specialty Pharmacy concluded that "US payers view PRO evidence from both clinical trials and real-world studies as useful for supplementing traditional clinical trial data when making oncology formulary decisions." The key word is "supplementing": PRO evidence reinforces the clinical and economic evidence; it does not substitute for it.
Designing a PRO strategy that serves both audiences
Start with payer evidence needs, not just regulatory needs
The typical PRO strategy is designed backward from the regulatory endpoint: what PRO instrument will FDA accept, what endpoint definition will survive FDA review, what label claim language can be supported. This approach is necessary but insufficient. The PRO strategy should also be designed backward from the payer evidence needs: what PRO concepts differentiate this product from existing therapies, what instruments are payers already familiar with in this therapeutic area, what MCID thresholds will the payer medical director apply, and what comparator data will the AMCP dossier require?
Dual-instrument strategy
Where feasible, include both a disease-specific instrument targeting the primary PRO concept and a broad, well-established generic instrument (such as the EQ-5D or SF-36) in the pivotal trial. The disease-specific instrument supports the regulatory endpoint and label claim. The generic instrument provides data that payers can use for cost-effectiveness modeling, quality-adjusted life year (QALY) calculations, and cross-therapy comparisons.
This adds patient burden, and the dual-instrument approach must be justified in the protocol. But the alternative is arriving at the AMCP dossier preparation stage without the data that payers need, which is the more costly failure mode.
Pre-specify responder analyses
In addition to the continuous PRO endpoint, pre-specify a responder analysis based on the MCID. This allows the AMCP dossier to present the proportion of patients achieving a clinically meaningful improvement, which is more intuitive for payer reviewers than a mean change score. If the MCID is not well-established for the chosen instrument, conduct a literature review during protocol development and document the MCID rationale in the statistical analysis plan.
Plan for comparative PRO evidence
If the pivotal trial uses a placebo comparator, plan a supplementary study or analysis that generates comparative PRO data against the most likely formulary comparators. This can be an indirect treatment comparison using patient-level data from prior trials, a network meta-analysis of published PRO data, or a prospective observational study launched concurrently with the pivotal trial. The AMCP dossier is strengthened substantially by comparative PRO evidence, even if it is indirect.
Extend PRO collection into the long-term follow-up
If the pivotal trial includes a long-term extension or follow-up period, continue PRO collection beyond the primary endpoint time point. Even if the primary analysis stops at week 24, PRO data at week 52 or later provide the payer with evidence of durability. Acknowledge the open-label limitation in the dossier, but present the data transparently with appropriate sensitivity analyses.
Generate real-world PRO evidence post-launch
For payer review, real-world PRO evidence collected through registries, chart reviews, or digital health platforms can supplement pivotal trial data. Payers increasingly reference real-world evidence in coverage decisions: a 2025 analysis of payer coverage decisions presented at AMCP Nexus found that for treatments on the market for 10 to 15 years, real-world evidence accounted for 14.1 percent of citations in coverage decisions, compared with 3.7 percent for treatments on the market for 1 to 5 years. This suggests that while real-world PRO evidence is less critical at launch, it becomes more important as the product matures and payers update their formulary reviews.
Practical recommendations
Engage payer advisory boards during Phase 2. Before locking the pivotal trial protocol, present the proposed PRO strategy to a payer advisory board. Ask specifically: what PRO instruments do you recognize, what MCID thresholds do you apply, and what comparative PRO evidence would you need to place this product on formulary?
Map the PRO strategy to the AMCP dossier sections. The AMCP Format 5.0 dossier sections on clinical evidence and economic modeling require specific PRO data inputs. Create a cross-reference between the pivotal trial PRO data collection plan and the dossier sections that will use those data. This mapping exercise often reveals gaps that are invisible when the PRO strategy is designed only for regulatory purposes.
Include PRO expertise on the AMCP dossier team. The dossier should be written by a team that includes a PRO specialist, not just a clinical writer and a health economist. The PRO specialist ensures that the PRO evidence is presented in terms that payer reviewers understand, including MCID-based responder rates, established instrument norms, and comparator-referenced effect sizes.
Document the PRO development story. FDA's COA Compendium and the DDT Qualification Program provide mechanisms for establishing the credibility of PRO instruments. If your product uses a novel instrument, pursue FDA qualification or at minimum document the development process thoroughly. Payers are more likely to accept novel instrument data when the instrument has been through a formal regulatory qualification pathway.
Sources
- FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. U.S. Food and Drug Administration, December 2009. https://www.fda.gov/media/77832/download
- FDA Patient-Focused Drug Development Guidance Series (Guidances 1-4). U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
- FDA Clinical Outcome Assessment (COA) Compendium. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-resources/clinical-outcome-assessment-compendium
- AMCP Format for Formulary Submissions, Version 5.0. Academy of Managed Care Pharmacy, 2024. https://www.amcp.org/sites/default/files/2024-04/AMCP-Format-5.0-JMCP-web_0.pdf
- Oderda GM, et al. "Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges." American Health and Drug Benefits. https://www.ahdbonline.com/articles/2165-patient-reported-outcomes-in-oncology-drug-labeling-in-the-united-states-a-framework-for-navigating-early-challenges
- Basch E, et al. "Patient-Reported Outcomes Are Changing the Landscape in Oncology Care: Challenges and Opportunities for Payers." American Health and Drug Benefits, 2013;6(5):264-274. https://www.ahdbonline.com/articles/1447-feature-1447
- "Implementing Patient-Reported Outcomes in Cancer Clinical Trials: A Closer Look at FDA's Draft Guidance and a Call to Action." Global Forum, DIA, July 2024. https://globalforum.diaglobal.org/issue/july-2024/implementing-patient-reported-outcomes-in-cancer-clinical-trials-a-closer-look-at-fdas-draft-guidance-and-a-call-to-action
- "PROs as Endpoints in Oncology Labeling Claims." Mapi Research Trust, January 2023. https://www.mapi-trust.org/resources/blog/2023/01/24/patient-reported-outcomes-oncology-labeling-claims-FDA-EMA
- JMCP Supplement, AMCP Nexus 2025 Poster Abstracts, Vol. 31, No. 10-d, October 2025. https://amcpnexus.org/sites/default/files/2025-11/JMCP%20Supplement%20-%20Nexus%202025%20Poster%20Abstracts.pdf
- Storf R, "The Impact of FDA and EMA Guidances Regarding Patient-Reported Outcomes on Drug Development and Approval." Master thesis, Heinrich Heine University Dusseldorf / DGRA. https://www.dgra.de/media/masterthesis/1277-master_storf_m.pdf
